Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis
Journal of Bone and Mineral Research, Volume 36, No. 5, Year 2021
Notification
URL copied to clipboard!
Description
Bisphosphonates are the first-line treatment for preventing fractures in osteoporosis patients. However, their use is contraindicated or to be used with caution in chronic kidney disease (CKD) patients, primarily because of a lack of information about their safety and effectiveness. We aimed to investigate the safety of oral bisphosphonates in patients with moderate to severe CKD, using primary-care electronic records from two cohorts, CPRD GOLD (1997–2016) and SIDIAP (2007–2015) in the UK and Catalonia, respectively. Both databases were linked to hospital records. SIDIAP was also linked to end-stage renal disease registry data. Patients with CKD stages 3b to 5, based on two or more estimated glomerular filtration rate measurements less than 45 mL/min/1.73 m2, aged 40 years or older were identified. New bisphosphonate users were propensity score–matched with up to five non-users to minimize confounding within this population. Our primary outcome was CKD stage worsening (estimated glomerular filtration rate [eGFR] decline or renal replacement therapy). Secondary outcomes were acute kidney injury, gastrointestinal bleeding/ulcers, and severe hypocalcemia. Hazard ratios (HRs) were estimated using Cox regression and Fine and Gray sub-HRs were calculated for competing risks. We matched 2447 bisphosphonate users with 8931 non-users from CPRD and 1399 users with 6547 non-users from SIDIAP. Bisphosphonate use was associated with greater risk of CKD progression in CPRD (sub-HR [95% CI]: 1.14 [1.04, 1.26]) and SIDIAP (sub-HR: 1.15 [1.04, 1.27]). No risk differences were found for acute kidney injury, gastrointestinal bleeding/ulcers, or hypocalcemia. Hence, we can conclude a modest (15%) increased risk of CKD progression was identified in association with bisphosphonate use. No other safety concerns were identified. Our findings should be considered before prescribing bisphosphonates to patients with moderate to severe CKD. © 2020 American Society for Bone and Mineral Research (ASBMR).
Authors & Co-Authors
Robinson, Danielle E.
Unknown Affiliation
Ali, M. Sanni
Unknown Affiliation
Pallarès, N.
Unknown Affiliation
Tebé, Cristian
Unknown Affiliation
Elhussein, Leena
Unknown Affiliation
Abrahamsen, Bo
Unknown Affiliation
Arden, Nigel K.
Unknown Affiliation
Ben-Shlomo, Yoav
Unknown Affiliation
Caskey, Fergus J.
Unknown Affiliation
Cooper, Cyrus C.
Unknown Affiliation
Dedman, Daniel
Unknown Affiliation
Delmestri, Antonella
Unknown Affiliation
Judge, Andrew D.
Unknown Affiliation
Pérez-Sáez, María José
Unknown Affiliation
Pascual, Julio F.
Unknown Affiliation
Nogués, Xavier
Unknown Affiliation
Díez-Pérez, Adolfo Diez
Unknown Affiliation
Strauss, Victoria Y.
Unknown Affiliation
Javaid, Muhammad Kassim
Unknown Affiliation
Prieto-Alhambra, D.
Unknown Affiliation
Statistics
Citations: 38
Authors: 20
Affiliations: 17
Identifiers
Doi:
10.1002/jbmr.4235
ISSN:
08840431
e-ISSN:
15234681
Research Areas
Environmental
Health System And Policy
Noncommunicable Diseases
Violence And Injury
Study Design
Cross Sectional Study
Cohort Study